MapLight Therapeutics (MPLT) Accumulated Expenses (2024 - 2025)
MapLight Therapeutics (MPLT) reported Accumulated Expenses of $6.2 million for Q4 2025, down 38.32% on a YoY basis from $10.0 million in Q4 2024, and up 54.24% sequentially from $4.0 million in Q3 2025.
MapLight Therapeutics (MPLT) Accumulated Expenses (2024 - 2025) Analysis & Trends
MapLight Therapeutics (MPLT) has 2 years of Accumulated Expenses data on file, last reported at $6.2 million in Q4 2025.
- For the quarter ending Q4 2025, Accumulated Expenses fell 38.32% year-over-year to $6.2 million; the trailing twelve-month figure through Dec 2025 stood at $6.2 million (down 38.32% YoY), and the FY2025 full-year result was $6.2 million, down 38.32% from the prior year.
- Accumulated Expenses advanced to $6.2 million in Q4 2025, from $4.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $10.0 million in Q4 2024 to a low of $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | MapLight Therapeutics | 305.82 Mn | 305.82 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.16 Mn |
| Sep 30, 2025 | 4.00 Mn |
| Dec 31, 2024 | 9.99 Mn |